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COVID-19 pandemic dilemmas: acute coronary syndrome, 
viral myocarditis or both?
Dylematy czasu pandemii COVID-19 — ostry zespół wieńcowy,  
wirusowe zapalenie mięśnia sercowego czy jedno i drugie?
Jan W. Pęksa●iD, Marek Klocek●iD, Magdalena Polaczyk●iD, Marek Rajzer●iD
Department of Cardiology, Interventional Electrocardiology and Hypertension, Institute of Cardiology, Jagiellonian University 
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Abstract
In December 2019, a new virus was identified — severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which 
quickly became the cause of a global pandemic. Due to the high infectivity of this virus, it was necessary to develop 
specific patterns of management for patients with acute cardiac problems dangerous to their health and life, associ-
ated with this pathogen. We present a middle-aged female infected with SARS-CoV-2, where acute coronary syndrome 
(ACS) was suspected due to reported chest pain, elevated cardiac markers and the presence of risk factors for ischemic 
heart disease. However, the coronary angiography did not show any atherosclerotic changes and, therefore, myocardial 
infarction with non-obstructive coronary arteries was diagnosed. Myocarditis secondary to SARS-CoV-2 infection could 
be a possible cause of ACS during coronary disease 20219 pandemic.
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Introduction
In 2020 the disease caused by a new coronavirus, SARS-
-CoV-2 (severe acute respiratory syndrome coronavirus 2), 
coronavirus disease 2019 (COVID-19), quickly spread to 
most regions of the world, causing not only numerous de-
aths but also significant changes to the health care systems 
in many countries [1, 2].
SARS-CoV-2 causes lower respiratory tract infections, 
with a potentially severe course, especially in people with 
older age and the presence of comorbidities such as obesi-
ty, hypertension (HTN), diabetes, heart failure, and cancer 
[3]. In the new epidemic situation, it has become difficult to 
maintain the proper standards of management in patients 
with life-threatening heart diseases accompanied by SARS-
-CoV-2 infection [4]. Previous logistical health care dilem-
mas — present before COVID-19 — coupled with the newer 
challenges of managing these patients [4–6].
Case report
A 43-year-old obese woman [body mass index (BMI) = 
= 33.5 kg/m2), with HTN and hypothyroidism was admitted 
urgently on November 6, 2020 to the Department of Car-
diology, Interventional Electrocardiology and Hypertension 
at Jagiellonian University Medical College Hospital, Kra-
ków, Poland from one of the district hospitals for further 
diagnosis and treatment. The patient reported pain in the 
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and body temperature 36.6ºC. There were no peripheral 
edema. The ECG recorded on admission is shown in Fi-
gure 1, and the results of laboratory tests in Table 1. The 
echocardiography revealed normal global contractility of 
the left ventricular muscle with an ejection fraction (EF) of 
about 65%, without segmental abnormalities of contractili-
ty. There were no signs of aortic dissection or valve defects 
as well as no fluid in the pericardial sac. Echocardiographic 
images in two projections are presented in Figures 2 and 3. 
The chest X-ray is shown in Figure 4.
Due to the overall clinical presentation, a history of 
chest pain, significantly elevated levels of highly-sensitive 
troponin (at admission 1,456 ng/L, normal < 47.3 ng/L), ele-
vated N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
concentration and presence of risk factors for ischemic 
heart disease (obesity, HTN), the patient was referred to 
the hospital’s CATH lab and qualified for invasive diagno-
sis of coronary vessels. Several hours before the proce-
dure, the woman received aspirin 1 × 300 mg, atorvasterol 
1 × 80 mg, and LMWH 1 × 80 mg s.c. However, the coronary 
angiography showed no atherosclerotic changes in the epi-
cardial arteries and no signs of slow peripheral blood flow.
In the following days, the patient was in good condi-
tion, without coughing and with a normal body tempera-
ture. Blood pressure ranged from 116–128/80–84 mm Hg. 
LMWH treatment was continued with 80 mg once daily s.c. 
Atorvastatin 80 mg, lercanidipine 20 mg, bisoprolol 5 mg 
chest that occurred the previous day, at rest. It radiated 
to the left upper limb, then subsided and recurred several 
times. From 2–3 days before this episode, the woman 
generally felt worse, had a dry cough, slight dyspnoea and 
no fever. The onset of COVID-19 symptoms (cough, fever 
up to 39°C and weakness) were on October 21, 2020. 
The first positive polymerase chain reaction test was on 
October 22, 2020.
During a 24-hour stay at district hospital, the concen-
tration of troponin I was elevated (values increasing from 
317 ng/L to 1,087 ng/L, the norm < 9 ng/L). The concentra-
tion of C-reactive protein (CRP) was normal and the D-dimer 
concentration was slightly increased. In the electrocardio-
gram (ECG), the sinus rhythm was about 75/min, without 
any significant deviations from the norm, blood pressure 
was also normal. Due to the persistence of chest discom-
fort, she was treated with morphine intravenously (i.v.) 
with a good effect, low-molecular-weight heparin (LMWH) 
1 × 60 mg subcutaneously (s.c.), acetylsalicylic acid (ASA) 
75 mg orally and dexamethasone 1 × 8 mg i.v. Previous 
treatment of the patient (for 2 years) included levothyro-
xine 100 µg, indapamide with prolonged release 1.5 mg, 
bisoprolol 5 mg and lercanidipine 20 mg all once daily.
At admission to our Department, the patient was in 
a good general condition with slight chest discomfort 
(5/10). The arterial blood pressure was 146/80 mm Hg, 
pulse 70/min, blood saturation 98% without oxygen therapy, 
Figure 1. Electrocardiogram on admission. Regular sinus rhythm, frequency approx. 70/min. Axis not deviated. PQ = 160 ms. QRS = 90 ms. 
QT = 400 ms. No significant changes to the ST-segment
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also were all given once daily. Physical rehabilitation was 
performed.
There was complete relief from the reported chest dis-
comfort and a decrease in troponin levels, and still there 
were no significant changes in subsequent ECGs. The re-
sults of laboratory tests of the patient on the day of dis-
charge from the Cardiology Department are presented in 
Table 1. The patient was discharged home after 3 days and 
on Day 19 from the first positive swab for SARS-CoV-2. The 
woman did not require further isolation [7]. The diagnosis 
of myocardial damage was made, possibly secondary to 
viral infection.
Discussion
In the described woman with COVID-19, an acute coronary 
syndrome (ACS) was initially suspected (chest pain and 
increase/decrease in blood cardiac troponin concentration 
were found), most likely in the form of a non-ST-segment 
elevation myocardial infarction (NSTEMI). Due to the exist-
ing risk factors (HTN, obesity, hypothyroidism), she was 
suspected having atherosclerotic lesions in the coronary 
arteries [8]. However, there were no ischemic changes on 
the ECG, no loss of myocardial viability (echocardiography), 
or blood flow disturbances on angiography [no thrombus in 
Table 1. The results of the patient’s laboratory tests on admission and on discharge
Tests [unit] Results on admission Results on discharge Normal range
Leukocytes [×103/µL] 7.26 5.43 4.0–10.0
Hemoglobin [g/dL] 12.5 12.0 12.0–16.0
Hematocrit [%] 38.8 36.6 37.0–47.0
Platelet count [×103/µL] 481 394 140–440
Natrium [mmol/L] 138 138 136–145
Potassium [mmol/L] 4.30 4.57 3.50–5.10
Urea [mmol/L] 3.21 5.56 2.76–8.07
Creatinine [µmol/L] 68.0 77.2 62.0–106.0
GFR, MDRD [ml/min/1.73 m2] 87 75 > 90
APTT [s] 34.1 – 26.0–36.0
INR 1.02 – 0.90–1.20
Glucose [mmol/L] 4.41 4.11 3.30–5.60
Troponin I hs [ng/L] 1,456.1 570.93 < 47.3
CK [U/L] 131 – 26–192
CK-MB mass [ng/mL] 4.44 1.71 < 5.00
LDH [U/L] 287 353 135–214
CRP [mg/L] 2.41 2.00 < 5.00
Procalcitonin [ng/mL] < 0.02 < 0.02 < 0.10
Interleukin 6 [pg/mL] 6.66 – < 7.00
Ferritin [µg/L] 28 – 13–400
Myoglobin [µg/L] 40 – < 110
D-dimers [mg/L] 0.81 0.68 < 0.55
NT-proBNP [pg/mL] 444 38 < 125
ALT [U/L] 55 44 10–35
AST [U/L] 40 34 10–35
TSH [µIU/mL] 1.720 – 0.270–4.200
Total cholesterol [mmol/L] – 3.5 3.2–5.2
HDL-cholesterol [mmol/L] – 0.97 > 1.2
LDL-cholesterol [mmol/L] – 2.0 < 3.4
Triglycerides [mmol/l] – 1.29 < 2.26
ALT — alanine aminotransferase; APTT — activated partial thromboplastin time; AST — aspartate aminotransferase; CK — creatine kinase; CK-MB mass — creatine kinase myocardial bound; CRP — C-reactive 
protein; GFR — glomerular filtration rate; HDL — high-density lipoprotein; INR — international normalized ratio; LDH — lactate dehydrogenase; LDL — low-density lipoprotein; MDRD — Modification of Diet  
in Renal Disease program; NT-proBNP — N-terminal pro-B-type natriuretic peptide; TSH — thyrotropic hormone
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all coronary arteries, with TIMI (Thrombolysis in Myocardial 
Infarction) 3 flow to the periphery] [9].
It may be suspected that the patient experienced “myo-
cardial infarction with non-obstructive coronary arteries” 
(no lesions narrowing the lumen by ≥ 50%) — MINOCA [8]. 
However, MINOCA is a working diagnosis that requires fur-
ther investigation to determine the cause of the patholo-
gy. Due to the confirmed SARS-CoV-2 infection, a viral eti-
ology of the heart damage was suspected. In our woman 
retrosternal symptoms appeared approximately 14 days 
after the first symptoms of COVID-19, thus, ongoing inflam-
mation could have triggered the release of troponins. On 
the other hand, the markers of inflammation [CRP, procal-
citonin, ferritin, interleukin 6 (IL-6), and myoglobin] were 
normal and the chest X-ray showed no evidence of infiltra-
tive changes in lungs.
The systematic review of 14 cases of myocarditis sec-
ondary to COVID-19 was published in August 2020 [5]. The 
authors found that COVID-19 myocarditis was slightly more 
common in men (58%), around the age of 50, the most com-
mon accompanying disease was HTN (33% of respondents), 
but 50% of cases had no comorbidities. Although ECGs did 
not show any pathology in some of these cases, troponin 
levels were elevated in 91% of the subjects. Echocardiog-
raphy showed a decreased left ventricular EF in 60% of pa-
tients. Among 14 documented cases of myocarditis, seven 
had no CRP test, two had normal CRP levels, and four had 
slightly elevated CRP values (10–20.7 mg/dL); only one had 
a very high level of CRP. In this group glucocorticoids were 
used most frequently in the treatment of myocarditis (58% 
of cases), but a significant percentage of patients were in 
a severe general condition [5]. The clinical and biochemi-
cal profile of our patient is in many domains similar to the 
cases included in the above mentioned review. Chronic 
steroid therapy and non-steroidal anti-inflammatory drugs 
were not initiated in our patient because of good general 
condition and no need for oxygen therapy. Moreover, the 
woman did not have increased CRP levels, had no fever, no 
fluid in the pericardial sac, and the administered retroster-
nal complaints subsided after a few days.
It cannot be ruled out that the cause of the chest com-
plaints reported by the patient and the observed increase 
in troponin levels may have been due to transient throm-
botic changes in the coronary artery. It could be caused 
either by a rupture or ulceration of an atherosclerotic le-
sion that does not significantly narrow the lumen of the 
artery, or by a mechanism of peripheral microembolism 
Figure 2. Echocardiography in the parasternal long axis projection. 
Normal dimensions of the left ventricle, left atrium, right ventricle 
and aorta are visible. Heart walls of normal thickness. No fluid in 
the pericardial sac
Figure 3. Echocardiography in 4-chambers apical projection. The 
correct proportion of the size of the left ventricle to the right ven-
tricle is visible. No fluid in the pericardial sac
Figure 4. Chest X-ray in antero-posterior view, in the supine posi-
tion. Pulmonary fields without infiltrative changes. Heart profile 
within the normal range for the supine position. Free diaphragm. 
The shadow of medical equipment projecting on the structures of 
the chest
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(coronary embolism). The physiological mechanisms of fi-
brinolysis and the treatment used before coronary angi-
ography (ASA and LMWH given to the patient both in the 
district hospital and in our Department) could dissolve the 
embolic material and restore normal blood flow (TIMI 3) in 
all coronary arteries.
In the discussed case, this suggestion may be re-
inforced by the observation of slightly, but still eleva-
ted D-dimer values. It is known that pulmonary, heart, 
brain and other organ microemboli are significant com-
plications of COVID-19. Moreover, infection with SARS-
-CoV-2 causes chronic dysfunction or damage to the 
vascular endothelium [10]. Eventually, the patient was 
diagnosed with a myocardial injury possibly secondary 
to a SARS-CoV-2 infection, and therefore would be called 
as a patient with “COVID-MINOCA” or “MINOCA caused 
by COVID-19”.
Conclusion
Myocarditis secondary to SARS-CoV-2 infection can be 
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Streszczenie
W grudniu 2019 roku zidentyfikowano nowy wirus — SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), 
który szybko stał się powodem światowej pandemii. Ze względu na dużą zakaźność wirusa konieczne było opraco-
wanie schematów postępowania z pacjentami z ostrymi problemami kardiologicznymi groźnymi dla zdrowia i życia 
(np. z zawałami serca, arytmiami), którym współtowarzyszyła infekcja tym patogenem. W pracy przedstawiono opis 
przypadku pacjentki zakażonej SARS-CoV-2, u której ze względu na zgłaszany ból w klatce piersiowej, podwyższone 
markery martwicy miokardium oraz obecność czynników ryzyka choroby niedokrwiennej serca rozpoznano ostry zespół 
wieńcowy (ACS). W wykonanej koronarografii nie uwidoczniono zmian miażdżycowych. W przebiegu infekcji SARS-CoV-2 
może także wystąpić zapalenie osierdzia lub mięśnia sercowego o etiologii wirusowej, które może również powodować 
podobne objawy do ACS.
Słowa kluczowe: COVID-19, zapalenie mięśnia sercowego, ostry zespół wieńcowy, MINOCA, opis przypadku
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